ArticleCase reports in endocrinology2026
Proinsulinoma Unmasked by Intermittent Fasting: A Case of Endogenous Proinsulinaemic Hypoglycaemia.
Article in Case reports in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Proinsulinoma Unmasked by Intermittent Fasting: A Case of Endogenous Proinsulinaemic Hypoglycaemia.Case reports in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report a 45-year-old man with recurrent fasting and post-prandial hypoglycaemia due to a proinsulin (PI)-secreting pancreatic neuroendocrine tumour (NET). During a supervised fast, plasma glucose fell to 1.8 mmol/L with detectable but low insulin (0.6 μU/L) and C-peptide (range 0.3-0.6 nmol/L). These concentrations did not meet diagnostic thresholds for endogenous hyperinsulinaemia proposed by the Endocrine Society, The North American Neuroendocrine Tumor Society (NANETS), or European Neuroendocrine Tumor Society (ENETS). In contrast, PI was markedly elevated at 33 pmol/L, exceeding all guideline cut-offs (≥5 pmol/L) and establishing PI-mediated hypoglycaemia. Cross-sectional imaging demonstrated a 16-mm arterially enhancing lesion in the pancreatic body, with intense somatostatin receptor expression on DOTATATE PET (SUVmax 18.0) and no evidence of metastatic disease. Histopathology confirmed a Grade 1 pancreatic NET, consistent with a localised proinsulinoma. This case highlights a diagnostic pitfall associated with contemporary insulin immunoassays, which have limited cross-reactivity with PI and may yield deceptively low insulin levels despite clinically significant endogenous hyperinsulinism. Routine measurement of PI during fasting evaluation is essential, particularly when insulin or C-peptide results appear discordant with the clinical phenotype, to avoid delayed diagnosis and facilitate timely curative intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.